Immune checkpoint inhibitors are a reality for the treatment of patients with NSCLC, and if approved for SCLC, would be a treatment breakthrough we have not seen for decades.
Leora Horn, MD, MSc
Advertisement
Articles by Leora Horn, MD, MSc
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Melanoma Trials You May Have Missed at ASCO 2026
2
Investigators Halt Phase 3 Trial of Sacituzumab Govitecan Combo in NSCLC
3
77 Updated Efficacy of Mutant-Selective PI3Kα Inhibitor Zovegalisib (RLY-2608) in Combination With Fulvestrant in Patients With PIK3CA-Mutant HR+/HER2– Advanced Breast Cancer: ReDiscover Trial
4
Subcutaneous Isatuximab Earns EU Approval in Multiple Myeloma
5